PICO 6 for ADHD og Misbrug

Review information

Authors

[Empty name][1]

[1][Empty affiliation]

Citation example: [Empty name]. PICO 6 for ADHD og Misbrug. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

Contact person

[Empty name]

Dates

Date of Search:	
Protocol First Published:	Not specified
Review First Published:	Not specified
Last Citation Issue:	Not specified

What's new

Date / Event	Description

History

Date / Event	Description

Abstract

Background

Objectives

Search methods

Selection criteria

Data collection and analysis

Main results

Authors' conclusions

Plain language summary

[Summary title]

[Summary text]

Background

Description of the condition

Description of the intervention

How the intervention might work

Why it is important to do this review

Objectives

Methods

Criteria for considering studies for this review

Types of studies

Types of participants

Types of interventions

Types of outcome measures

Primary outcomes

Secondary outcomes

Search methods for identification of studies

Electronic searches

Searching other resources

Data collection and analysis

Selection of studies

Data extraction and management

Assessment of risk of bias in included studies

Measures of treatment effect

Unit of analysis issues

Dealing with missing data

Assessment of heterogeneity

Assessment of reporting biases

Data synthesis

Subgroup analysis and investigation of heterogeneity

Sensitivity analysis

Results

Description of studies

Results of the search

Included studies

Excluded studies

Risk of bias in included studies

Allocation (selection bias)

Blinding (performance bias and detection bias)

Incomplete outcome data (attrition bias)

Selective reporting (reporting bias)

Other potential sources of bias

Effects of interventions

Discussion

Summary of main results

Overall completeness and applicability of evidence

Quality of the evidence

Potential biases in the review process

Agreements and disagreements with other studies or reviews

Authors' conclusions

Implications for practice

Implications for research

Acknowledgements

Contributions of authors

Declarations of interest

Differences between protocol and review

Published notes

Characteristics of studies

Characteristics of included studies

Riggs 2011

Methods	RCT
Participants	303 børn og unge med ADHD
Interventions	OROS MPH + CBT versus Placebo + CBT
Outcomes	ADHD kernesymptomer (forældre), Funktionsniveau (kliniker), Misbrug, SAE, Bivirkninger

Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer genereret
Allocation concealment (selection bias)	Low risk	Ikke angivet
Blinding of participants and personnel (performance bias)	Low risk	Deltagere blindet, personel??
Blinding of outcome assessment (detection bias)	Unclear risk	Ikke angivet
Incomplete outcome data (attrition bias)	Low risk	Ikke angivet
Selective reporting (reporting bias)	Low risk	alle outcomes rapporteret
Other bias	Low risk	Ingen umiddelbare

Thurstone 2011

Methods	RCT
Participants	70 deltagere
Interventions	Atomoxetin + MI/CBT
Outcomes	ADHD kernesymptomer (forældre), Funktionsniveau (kliniker), Misbrug, SAE, Bivirkninger, frafald pga bivirkninger
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Ikke angivet
Allocation concealment (selection bias)	Unclear risk	Ikke angivet
Blinding of participants and personnel (performance bias)	Unclear risk	Deltagere: low - personnel: high (vidste hvem der fik hvilken medicin)
Blinding of outcome assessment (detection bias)	Low risk	all other staff were blind to medicine assignment
Incomplete outcome data (attrition bias)	Low risk	7% drop outs
Selective reporting (reporting bias)	Low risk	alle outcomes rapporteret
Other bias	Low risk	ingen umiddelbare

Winhusen 2011

Methods	RCT
Participants	Som Riggs 2011
Interventions	som Riggs 2011
Outcomes	som Riggs 2011
Notes	Eneste forskel på Riggs 2011 er præsentation af andre tidsskalaer der er målt på

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	computer genereret
Allocation concealment (selection bias)	Unclear risk	ikke angivet
Blinding of participants and personnel (performance bias)	Low risk	Deltagere blindet, personel??
Blinding of outcome assessment (detection bias)	Unclear risk	ikke angivet

Incomplete outcome data (attrition bias)	Unclear risk	dropouts ikke angivet
Selective reporting (reporting bias)	Low risk	alle outcomes rapporteret (se Riggs 2011)
Other bias	Low risk	ingen umiddelbare

Footnotes

Characteristics of excluded studies

Footnotes

Characteristics of studies awaiting classification

Footnotes

Characteristics of ongoing studies

Footnotes

Summary of findings tables

Additional tables

References to studies

Included studies

Riggs 2011

[Empty]

Thurstone 2011

[Empty]

Winhusen 2011

[Empty]

Excluded studies

Studies awaiting classification

Ongoing studies

Other references

Additional references

Other published versions of this review

Data and analyses

1 Methylphenidat+CBT versus placebo+CBT

Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
1.1 Funktionsniveau klinikerbedømt (16 uger)	1	285	Risk Ratio (M-H, Fixed, 95% CI)	1.23 [0.79, 1.93]
1.2 ADHD kernesymptom forældrebedømt (8 uger)	1	164	Mean Difference (IV, Fixed, 95% CI)	4.40 [0.85, 7.95]
1.3 Dage med misbrug pr 28 dage (16 uger)	1	285	Mean Difference (IV, Fixed, 95% CI)	-0.50 [-2.95, 1.95]
1.4 Misbrug, antal negative urinprøver (16 uger)	1	285	Mean Difference (IV, Fixed, 95% CI)	1.00 [-0.05, 2.05]
1.5 SAE (EoT)	1	303	Risk Ratio (M-H, Fixed, 95% CI)	0.57 [0.17, 1.90]

1.6 Bivirkninger (EoT)	1	303	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.83, 1.33]

2 Atomoxetin+MI/CBT versus placebo+MI/CBT

Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
2.1 Funktionsniveau klinikerbedømt (12 uger)	1	65	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.57, 1.34]
2.2 ADHD kernesymptom forældrebedømt (12 uger)	1	70	Mean Difference (IV, Fixed, 95% CI)	5.00 [-1.88, 11.88]
2.3 Dage med misbrug pr 28 dage (12 uger)	1	70	Mean Difference (IV, Fixed, 95% CI)	-3.54 [-8.21, 1.13]
2.4 Misbrug, antal neg urinprøver (16 uger)	1	65	Mean Difference (IV, Fixed, 95% CI)	-0.08 [-4.53, 4.37]
2.5 SAE (EoT)	1	70	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.07, 15.36]
2.6 Bivirkninger (EoT)	1	70	Risk Ratio (M-H, Fixed, 95% CI)	1.41 [0.94, 2.12]

3 Aktiv behandling (subgr Met / Atx)

Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
3.1 Funktionsniveau klinikerbedømt (CGI-I)	2		Odds Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1.1 Methylphenidat	1	285	Odds Ratio (M-H, Fixed, 95% CI)	1.31 [0.74, 2.31]
3.1.2 Atomoxetin	1	65	Odds Ratio (M-H, Fixed, 95% CI)	0.74 [0.28, 1.97]
3.2 Alvorlige bivirkninger (SAE) (EoT)	2		Odds Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.2.1 Methylphenidat	1	303	Odds Ratio (M-H, Fixed, 95% CI)	0.56 [0.16, 1.97]
3.2.2 Atomoxetin	1	70	Odds Ratio (M-H, Fixed, 95% CI)	1.00 [0.06, 16.65]

3.3 Bivirkninger (EoT)	2		Odds Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.3.1 Methylphenidat	1	303	Odds Ratio (M-H, Fixed, 95% CI)	1.10 [0.70, 1.72]
3.3.2 Atomoxetin	1	70	Odds Ratio (M-H, Fixed, 95% CI)	2.31 [0.87, 6.12]
3.4 ADHD kernesymptomer klinker/observatør bedømt	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.4.1 Methylphenidat	1	164	Mean Difference (IV, Random, 95% CI)	-2.00 [-4.93, 0.93]
3.4.2 Atomoxetin	1	70	Mean Difference (IV, Random, 95% CI)	-0.83 [-7.54, 5.88]
3.5 ADHD kernesymptom forældrebedømt ADHD-RS	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.5.1 Methylphenidat	1	164	Mean Difference (IV, Fixed, 95% CI)	4.40 [0.85, 7.95]
3.5.2 Atomoxetin	1	70	Mean Difference (IV, Fixed, 95% CI)	5.00 [-1.88, 11.88]
3.6 Dage med misbrug pr 28 dage	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.6.1 Methylphenidat	1	285	Mean Difference (IV, Fixed, 95% CI)	-0.50 [-2.95, 1.95]
3.6.2 Atomoxetin	1	70	Mean Difference (IV, Fixed, 95% CI)	-3.54 [-8.21, 1.13]
3.7 Misbrug, antale negative urinprøver	2		Std. Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.7.1 Methylphenidat	1	285	Std. Mean Difference (IV, Fixed, 95% CI)	0.22 [-0.01, 0.45]
3.7.2 Atomoxetin	1	65	Std. Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.49, 0.48]

Figures

Figure 1 (Analysis 1.1)

Forest plot of comparison: 1 Methylphenidat+CBT versus placebo+CBT, outcome: 1.1 Funktionsniveau klinikerbedømt (16 uger).

Figure 2 (Analysis 1.2)

Forest plot of comparison: 1 Methylphenidat+CBT versus placebo+CBT, outcome: 1.2 ADHD kernesymptom forældrebedømt (8 uger).

Figure 3 (Analysis 1.5)

Forest plot of comparison: 1 Methylphenidat+CBT versus placebo+CBT, outcome: 1.5 SAE (EoT).

Figure 4 (Analysis 3.1)

Forest plot of comparison: 3 Aktiv behandling (subgr Met / Atx), outcome: 3.1 Funktionsniveau klinikerbedømt (CGI-I).

Sources of support

Internal sources

- No sources of support provided

External sources

- No sources of support provided

Feedback

Appendices

1 Methylphenidat+CBT versus placebo+CBT

1.1 Funktionsniveau klinikerbedømt (16 uger)

Study or Subgroup	methylphenidat + CBT Events	Total	placebo + CBT Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Riggs 2011	34	144	27	141	100.0%	1.23 [0.79, 1.93]
Total (95% CI)		**144**		**141**	**100.0%**	**1.23 [0.79, 1.93]**
Total events	34		27			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.91 (P = 0.36)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

1.2 ADHD kernesymptom forældrebedømt (8 uger)

Study or Subgroup	methylphenidat + CBT Mean	SD	Total	placebo + CBT Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
Riggs 2011	-26	10.5	85	-30.4	12.5	79	100.0%	4.40 [0.85, 7.95]
Total (95% CI)			**85**			**79**	**100.0%**	**4.40 [0.85, 7.95]**

Heterogeneity: Not applicable
Test for overall effect: Z = 2.43 (P = 0.02)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

1.3 Dage med misbrug pr 28 dage (16 uger)

Study or Subgroup	methylphenidat + CBT Mean	SD	Total	placebo + CBT Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
Riggs 2011	-5.7	10.3203	144	-5.2	10.8109	141	100.0%	-0.50 [-2.95, 1.95]
Total (95% CI)			**144**			**141**	**100.0%**	**-0.50 [-2.95, 1.95]**

Heterogeneity: Not applicable
Test for overall effect: Z = 0.40 (P = 0.69)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

1.4 Misbrug, antal negative urinprøver (16 uger)

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
Riggs 2011	3.8	4.8566	144	2.8	4.2043	141	100.0%	1.00 [-0.05, 2.05]
Total (95% CI)			**144**			**141**	**100.0%**	**1.00 [-0.05, 2.05]**

Heterogeneity: Not applicable
Test for overall effect: Z = 1.86 (P = 0.06)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

1.5 SAE (EoT)

Study or Subgroup	methylphenidat + CBT Events	Total	placebo + CBT Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Riggs 2011	4	152	7	151	100.0%	0.57 [0.17, 1.90]
Total (95% CI)		**152**		**151**	**100.0%**	**0.57 [0.17, 1.90]**
Total events	4		7			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.92 (P = 0.36)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

1.6 Bivirkninger (EoT)

Study or Subgroup	Atomoxetin Events	Total	Placebo Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Riggs 2011	74	151	71	152	100.0%	1.05 [0.83, 1.33]
Total (95% CI)		**151**		**152**	**100.0%**	**1.05 [0.83, 1.33]**
Total events	74		71			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.40 (P = 0.69)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

2 Atomoxetin+MI/CBT versus placebo+MI/CBT

2.1 Funktionsniveau klinikerbedømt (12 uger)

Study or Subgroup	Atomoxetin + MI/CBT Events	Total	placebo + MI/CBT Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Thurstone 2011	17	32	20	33	100.0%	0.88 [0.57, 1.34]
Total (95% CI)		**32**		**33**	**100.0%**	**0.88 [0.57, 1.34]**
Total events	17		20			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.61 (P = 0.54)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

2.2 ADHD kernesymptom forældrebedømt (12 uger)

Study or Subgroup	Atomoxetin + MI/CBT Mean	SD	Total	placebo + MI/CBT Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
Thurstone 2011	13.82	13.4202	35	8.82	15.8655	35	100.0%	5.00 [-1.88, 11.88]
Total (95% CI)			**35**			**35**	**100.0%**	**5.00 [-1.88, 11.88]**

Heterogeneity: Not applicable
Test for overall effect: Z = 1.42 (P = 0.15)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

2.3 Dage med misbrug pr 28 dage (12 uger)

Study or Subgroup	Atomoxetin+ MI/CBT Mean	SD	Total	Placebo+MI/CBT Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
Thurstone 2011	-5.78	9.9851	35	-2.24	9.956	35	100.0%	-3.54 [-8.21, 1.13]
Total (95% CI)			**35**			**35**	**100.0%**	**-3.54 [-8.21, 1.13]**

Heterogeneity: Not applicable
Test for overall effect: Z = 1.49 (P = 0.14)





Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

2.4 Misbrug, antal neg urinprøver (16 uger)

Study or Subgroup	Atomoxetin + MI/CBT Mean	SD	Total	placebo + MI/CBT Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
Thurstone 2011	1.03	9.15	32	1.11	9.15	33	100.0%	-0.08 [-4.53, 4.37]
Total (95% CI)			**32**			**33**	**100.0%**	**-0.08 [-4.53, 4.37]**

Heterogeneity: Not applicable
Test for overall effect: Z = 0.04 (P = 0.97)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

2.5 SAE (EoT)

Study or Subgroup	Atomoxetin + MI/CBT Events	Total	placebo + MI/CBT Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Thurstone 2011	1	35	1	35	100.0%	1.00 [0.07, 15.36]
Total (95% CI)		**35**		**35**	**100.0%**	**1.00 [0.07, 15.36]**
Total events	1		1			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

2.6 Bivirkninger (EoT)

Study or Subgroup	Atomoxetin + MI/CBT Events	Total	placebo + MI/CBT Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Thurstone 2011	24	35	17	35	100.0%	1.41 [0.94, 2.12]
Total (95% CI)		**35**		**35**	**100.0%**	**1.41 [0.94, 2.12]**
Total events	24		17			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.66 (P = 0.10)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

3 Aktiv behandling (subgr Met / Atx)

3.1 Funktionsniveau klinikerbedømt (CGI-I)

Study or Subgroup	aktiv behandling Events	Total	placebo Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI
3.1.1 Methylphenidat						
Riggs 2011 (1)	34	144	27	141	100.0%	1.31 [0.74, 2.31]
Subtotal (95% CI)		**144**		**141**	**100.0%**	**1.31 [0.74, 2.31]**
Total events	34		27			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.92 (P = 0.36)						
3.1.2 Atomoxetin						
Thurstone 2011 (2)	17	32	20	33	100.0%	0.74 [0.28, 1.97]
Subtotal (95% CI)		**32**		**33**	**100.0%**	**0.74 [0.28, 1.97]**
Total events	17		20			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.61 (P = 0.54)						



Test for subgroup differences: Chi² = 0.97, df = 1 (P = 0.32), I² = 0%

Footnotes

(1) Riggs: OROS-MPH+CBT vs Placebo+CBT

(2) Thurstone: ATX+MI/CBT vs Placebo+MI/CBT

Risk of bias legend

(**A**) Random sequence generation (selection bias)

(**B**) Allocation concealment (selection bias)

(**C**) Blinding of participants and personnel (performance bias)

(**D**) Blinding of outcome assessment (detection bias)

(**E**) Incomplete outcome data (attrition bias)

(**F**) Selective reporting (reporting bias)

(**G**) Other bias

3.2 Alvorlige bivirkninger (SAE) (EoT)



Test for subgroup differences: Chi² = 0.13, df = 1 (P = 0.72), I² = 0%

Footnotes

(1) Riggs: OROS-MPH+CBT vs Placebo+CBT

(2) Thurstone: ATX+MI/CBT vs Placebo+MI/CBT

Risk of bias legend

(**A**) Random sequence generation (selection bias)

(**B**) Allocation concealment (selection bias)

(**C**) Blinding of participants and personnel (performance bias)

(**D**) Blinding of outcome assessment (detection bias)

(**E**) Incomplete outcome data (attrition bias)

(**F**) Selective reporting (reporting bias)

(**G**) Other bias

3.3 Bivirkninger (EoT)

Study or Subgroup	Aktivbehandling Events	Total	Placebo Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI
3.3.1 Methylphenidat						
Riggs 2011 (1)	74	151	71	152	100.0%	1.10 [0.70, 1.72]
Subtotal (95% CI)		**151**		**152**	**100.0%**	**1.10 [0.70, 1.72]**
Total events	74		71			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.40 (P = 0.69)						
3.3.2 Atomoxetin						
Thurstone 2011 (2)	24	35	17	35	100.0%	2.31 [0.87, 6.12]
Subtotal (95% CI)		**35**		**35**	**100.0%**	**2.31 [0.87, 6.12]**
Total events	24		17			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.68 (P = 0.09)						



Test for subgroup differences: Chi² = 1.85, df = 1 (P = 0.17), I² = 46.0%

Footnotes

(1) Riggs: OROS-MPH+CBT vs Placebo+CBT

(2) Thurstone: ATX+MI/CBT vs Placebo+MI/CBT

Risk of bias legend

(**A**) Random sequence generation (selection bias)

(**B**) Allocation concealment (selection bias)

(**C**) Blinding of participants and personnel (performance bias)

(**D**) Blinding of outcome assessment (detection bias)

(**E**) Incomplete outcome data (attrition bias)

(**F**) Selective reporting (reporting bias)

(**G**) Other bias

3.4 ADHD kernesymptomer klinker/observatør bedømt

Study or Subgroup	aktivbehandling Mean	SD	Total	placebo Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
3.4.1 Methylphenidat								
Riggs 2011 (1)	19.2	9.736	85	21.2	9.3755	79	100.0%	-2.00 [-4.93, 0.93]
Subtotal (95% CI)			**85**			**79**	**100.0%**	**-2.00 [-4.93, 0.93]**
Heterogeneity: Not applicable								
Test for overall effect: Z = 1.34 (P = 0.18)								
3.4.2 Atomoxetin								
Thurstone 2011 (2)	18.19	13.9151	35	19.02	14.7011	35	100.0%	-0.83 [-7.54, 5.88]
Subtotal (95% CI)			**35**			**35**	**100.0%**	**-0.83 [-7.54, 5.88]**
Heterogeneity: Not applicable								
Test for overall effect: Z = 0.24 (P = 0.81)								



Test for subgroup differences: Chi² = 0.10, df = 1 (P = 0.75), I² = 0%

Footnotes

(1) Riggs: OROS-MPH+CBT vs Placebo+CBT

(2) Thurstone: ATX+MI/CBT vs Placebo+MI/CBT

Risk of bias legend

(**A**) Random sequence generation (selection bias)

(**B**) Allocation concealment (selection bias)

(**C**) Blinding of participants and personnel (performance bias)

(**D**) Blinding of outcome assessment (detection bias)

(**E**) Incomplete outcome data (attrition bias)

(**F**) Selective reporting (reporting bias)

(**G**) Other bias

3.5 ADHD kernesymptom forældrebedømt ADHD-RS

Study or Subgroup	aktiv behandling Mean	SD	Total	placebo Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
3.5.1 Methylphenidat								
Riggs 2011 (1)	-26	10.5	85	-30.4	12.5	79	100.0%	4.40 [0.85, 7.95]
Subtotal (95% CI)			**85**			**79**	**100.0%**	**4.40 [0.85, 7.95]**
Heterogeneity: Not applicable								
Test for overall effect: Z = 2.43 (P = 0.02)								
3.5.2 Atomoxetin								
Thurstone 2011 (2)	13.82	13.4202	35	8.82	15.8655	35	100.0%	5.00 [-1.88, 11.88]
Subtotal (95% CI)			**35**			**35**	**100.0%**	**5.00 [-1.88, 11.88]**
Heterogeneity: Not applicable								
Test for overall effect: Z = 1.42 (P = 0.15)								



Test for subgroup differences: Chi² = 0.02, df = 1 (P = 0.88), I² = 0%

Footnotes

(1) Riggs: OROS-MPH+CBT vs Placebo+CBT

(2) Thurstone: ATX+MI/CBT vs Placebo+MI/CBT

Risk of bias legend

(**A**) Random sequence generation (selection bias)

(**B**) Allocation concealment (selection bias)

(**C**) Blinding of participants and personnel (performance bias)

(**D**) Blinding of outcome assessment (detection bias)

(**E**) Incomplete outcome data (attrition bias)

(**F**) Selective reporting (reporting bias)

(**G**) Other bias

3.6 Dage med misbrug pr 28 dage

Study or Subgroup	aktiv behandling Mean	SD	Total	placebo Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
3.6.1 Methylphenidat								
Riggs 2011 (1)	-5.7	10.3203	144	-5.2	10.8109	141	100.0%	-0.50 [-2.95, 1.95]
Subtotal (95% CI)			**144**			**141**	**100.0%**	**-0.50 [-2.95, 1.95]**
Heterogeneity: Not applicable								
Test for overall effect: Z = 0.40 (P = 0.69)								
3.6.2 Atomoxetin								
Thurstone 2011 (2)	-5.78	9.9851	35	-2.24	9.956	35	100.0%	-3.54 [-8.21, 1.13]
Subtotal (95% CI)			**35**			**35**	**100.0%**	**-3.54 [-8.21, 1.13]**
Heterogeneity: Not applicable								
Test for overall effect: Z = 1.49 (P = 0.14)								



Test for subgroup differences: Chi² = 1.27, df = 1 (P = 0.26), I² = 21.6%

Footnotes

(1) Riggs: OROS-MPH+CBT vs Placebo+CBT

(2) Thurstone: ATX+MI/CBT vs Placebo+MI/CBT

Risk of bias legend

(**A**) Random sequence generation (selection bias)

(**B**) Allocation concealment (selection bias)

(**C**) Blinding of participants and personnel (performance bias)

(**D**) Blinding of outcome assessment (detection bias)

(**E**) Incomplete outcome data (attrition bias)

(**F**) Selective reporting (reporting bias)

(**G**) Other bias

3.7 Misbrug, antale negative urinprøver

Study or Subgroup	aktivbehandling Mean	SD	Total	placebo Mean	SD	Total	Weight	Std. Mean Difference IV, Fixed, 95% CI
3.7.1 Methylphenidat								
Riggs 2011 (1)	3.8	4.8566	144	2.8	4.2043	141	100.0%	0.22 [-0.01, 0.45]
Subtotal (95% CI)			**144**			**141**	**100.0%**	**0.22 [-0.01, 0.45]**
Heterogeneity: Not applicable								
Test for overall effect: Z = 1.85 (P = 0.06)								
3.7.2 Atomoxetin								
Thurstone 2011 (2)	1.03	9.15	32	1.11	9.15	33	100.0%	-0.01 [-0.49, 0.48]
Subtotal (95% CI)			**32**			**33**	**100.0%**	**-0.01 [-0.49, 0.48]**
Heterogeneity: Not applicable								
Test for overall effect: Z = 0.03 (P = 0.97)								



Test for subgroup differences: Chi² = 0.69, df = 1 (P = 0.41), I² = 0%

Footnotes

(1) Riggs: OROS-MPH+CBT vs Placebo+CBT

(2) Thurstone: ATX+MI/CBT vs Placebo+MI/CBT

Risk of bias legend

(**A**) Random sequence generation (selection bias)

(**B**) Allocation concealment (selection bias)

(**C**) Blinding of participants and personnel (performance bias)

(**D**) Blinding of outcome assessment (detection bias)

(**E**) Incomplete outcome data (attrition bias)

(**F**) Selective reporting (reporting bias)

(**G**) Other bias